Clinical Trials in Romania

• A 24-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma (EXHALE-4) Ended
  2023-509739-22-00 Phase III Eosinophilic asthma Areteia Therapeutics Inc.
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 Phase III Chronic Obstructive Pulmonary Disease (COPD) Astrazeneca AB
• A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twel… Ended
  2023-509243-27-00 Phase II Moderate-to-Severe Uncontrolled Asthma AstraZeneca AB
• A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants with Advanced/Metastatic Non-Sq… Ended
  2022-500608-23-00 Phase II Previously Untreated MET Amplified Locally Advanced/Metastat… Abbvie Deutschland GmbH & Co. KG
• A Study to Evaluate Investigational Therapies in Chronic Hepatitis B Virus Infection Ended
  2024-513176-17-00 Phase II Chronic Hepatitis B Virus (HBV) Infection Vir Biotechnology Inc.
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus place… Ended
  2024-512420-10-00 Phase I (Other) Plaque psoriasis Boehringer Ingelheim International GmbH; Boehringer Ingelheim RCV GmbH & Co. KG
• A study to evaluate the efficacy and safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 Ended
  2023-504540-33-00 Phase III COVID-19 Atea Pharmaceuticals Inc.
• A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509783-23-00 Phase II Diffuse Cutaneous Systemic Sclerosis Horizon Therapeutics Ireland Designated Activity Company
• A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)] Ended
  2022-501426-38-00 Phase II Lipoprotein Disorder Eli Lilly & Co.
• A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection Ended
  2022-501901-10-00 Phase IV Chronic Hepatitis D Infection Gilead Sciences Inc.
• Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasth… Ended
  2024-512258-91-00 Phase III Generalized Myasthenia Gravis (gMG) Immunovant Sciences GmbH
• Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 2) Ended
  2023-504238-23-00 Phase III Hepatitis B, Chronic Glaxosmithkline Research & Development Limited
• Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 1) Ended
  2023-504239-41-00 Phase III Hepatitis B, Chronic Glaxosmithkline Research & Development Limited
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended
  2023-508528-36-00 Phase III Resected squamous cell carcinoma of the head and neck Merck Healthcare KGaA
• A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptoms Ended
  2022-500332-11-00 Phase II systemic sclerosis Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH; Boehr…
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended
  2023-503794-38-00 Phase III Prevention of stroke or systemic embolism in atrial fibrilla… Bayer AG
• A long-term study to evaluate if KVD900 is safe and effective in treating attacks in patients with Hereditary Angioedema. Ended
  2023-505904-41-00 Phase III Hereditary Angioedema Type I or II Kalvista Pharmaceuticals Limited
• A study to test the safety of MK-1654 and how well MK-1654 works in healthy infants Ended
  2022-500350-42-01 Phase II/III Prevention of RSV Merck Sharp & Dohme Corp.
• Zibotentan and Dapagliflozin combination, Evaluated in Liver cirrhosis (ZEAL study) Ended
  2023-505405-17-00 Phase II Liver cirrhosis with features of portal hypertension. Astrazeneca AB
• Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia Ended
  2023-508433-14-00 Phase III Schizophrenia Neurocrine Biosciences Inc.
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 Phase III Gastric and Gastroesophageal Junction Cancer With FGFR2b Ove… Amgen Inc.
• A research study to look into how semaglutide, together with a lower dose of insulin glargine, compares to a higher dose of insulin glargine… Ended
  2024-510612-75-00 Phase III Participants with T2D and overweight Novo Nordisk A/S
• A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or … Ended
  2023-504257-12-00 Phase II Portal hypertension Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH; Boehr…
• Open-label trial to check the safety and tolerability of RTX-GRT7039 injections for pain associated with osteoarthritis of the knee. Ended
  2024-515709-24-00 Phase III Moderate to severe pain associated with Osteoarthritis of th… Gruenenthal GmbH

Showing 745–768 of 865 trials